食管心房调搏与胺碘酮治疗阵发性室上性心动过速的即时疗效比较

阵发性室上性心动过速（PSVT）是常见的心律失常，是心血管常见急症。当其发作时心室率较快，发作时间较长时。可导致休克、阿一斯综合征、心绞痛、急性心肌梗死，甚至猝死。有器质性心脏病者及年长者尽快终止其发作尤其重要。经过应用经食管心房调搏（TEAP）治疗42例PSVT并与42例采用胺碘酮静脉注射法进行比较，旨在了解二者的临床疗效及安全性。现报告如下：     

根治性切除治疗胰头癌的手术体会

目的 总结提高胰头癌手术根治率和降低术后并发症发生率的经验。方法 回顾性分析我院1996年1月至2005年3月期间的55例胰头癌根治术患者的临床资料。结果 本组55例胰头癌根治性切除术患者中男31例，女24例，均为胰腺导管癌。2002年前、后根治率分别为25．9％（29／112）和34．7％（26／75），并发症发生率分别为48．3％（14／29）和19．2％（5／26）。提高根治性手术技巧包括胰周淋巴结及神经丛清扫、联合血管切除、综合无血术野技术等。结论 提高胰头癌手术根治率和降低术后并发症发生率有赖于对胰头癌病理生理特点的深入了解和手术技巧的成熟。     

二氢青蒿素对胰腺癌生长的抑制作用

Objective To investigate the anti-tumor activity of dihydroartemisinin in pancreatic cancer in vitro and in vivo. Methods For cultured cells,cell growth was determined by the MTT assay and apoptosis was evaluated by flow cytometry analysis stained with Annexin V-FITG/PI. The protein expression in BxPC-3 cells was analyzed by Western blot assay. BxPC-3 cells were injected subcutaneously into nude mice to establish pancreatic xenograft tumors and the tumor volume was monitored after exposure to dihydroartemisinin. Ki-67 staining and TUNEL assay were used to assess tumor cell proliferation and apoptosis in tumor tissue. Results After treatment by dihydroartemisinin in vitro, the proliferative inhibition rates of pancreatic cancer cells BxPC-3 and AsPC-1 reached up to (76.2 ± 3.5) % and (79.5 ± 2.9) %, and the apoptosis rates were up to (55.5 ± 3.2)% and (40.0 ± 3.5)%, the differences were significantly (P ＜ 0.01) compared with control [(2.0 ± 1.3) % and (0.9 ± 0.4) %]. Dihydroartemisinin inhibited the growth of pancreatic xenograft tumors in nude mice. The proliferation index and apoptusis index were (49.1 ± 3.9)% and (50.2 ± 4.4)% respectively in dihydroarternisinin 50 mg/kg treatment group, compared to those of (72.1 ± 3.3) % and (9.4 ± 2.9) % in control, the differences were significantly (P ＜0.01). Western blot assay indicated that dihydroartemisinin up-regulates expression of proliferation-associated protein p21WAF1 and down-regulates expression of PCNA, increases expression of apoptosis-associated protein Bax and decreases expression of Bcl-2 and activates caspase-9 in BxPC-3 cells. Conclusions Dihydroartemisinin exerts anti-tumor activity in pancreatic cancer both in vitro and in vivo by proliferation inhibition and apoptusis induction. Dihydroartemisinin can be used as a potential anti-tumor drug in pancreatic cancer.     

利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化*

目的 探讨应用利拉鲁肽治疗非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者血脂、血管内皮功能和血清肝纤维化指标的变化。方法 2014年1月～2018年12月我院收治的NAFLD合并T2DM患者90例,被随机分为对照组45例和观察组45例,分别给予二甲双胍或二甲双胍联合利拉鲁肽治疗12周。检测空腹血糖(FPG)、餐后 2 h 血糖(2hPPG)和糖化血红蛋白(HbA1c),使用高分辨超声诊断仪检测肱动脉内径变化,记录血管舒张内径达到最大值所需的时间(T₁)和舌下含化硝酸甘油后血管达最大内径所需的时间(T₂),计算肱动脉血流介导的内皮依赖性血管舒张功能(EDR)和硝酸甘油介导的内皮非依赖性血管舒张功能(END)。采用放射免疫分析法检测血清透明质酸(HA)、 层粘连蛋白(LN)、 IV型胶原(CIV)和 III型前胶原(PIIIP)。结果 在治疗结束时,观察组和对照组FPG分别为(7.3±1.9)mmol/L对(8.6±1.8)mmol/L,2hPPG分别为(9.8±2.3)mmol/L对(11.4±2.2)mmol/L,HbA1c水平分别为(7.2±1.0)%对(8.3±1.2)%,差异显著(P＜0.05);血清TC分别为(4.8±0.9)mmol/L对(5.6±1.2)mmol/L、TG分别为(1.5±0.4)mmol/L对(2.0±0.6)mmol/L、LDL-C分别为(2.0±0.6)mmol/L对(2.9±0.7)mmol/L和HDL-C分别为(1.6±0.3)mmol/L对(1.3±0.2)mmol/L,差异显著(P＜0.05);T₁分别为(56.1±6.5)s对(62.9±5.8)s,EDR分别为(7.8±1.0)%对(5.2±0.8)%和END分别为(21.3±2.9)%对(17.2±2.5)%,差异显著(P＜0.05);血清HA分别为(70.3±9.2)ng/ml对(85.9±10.3)ng/ml, CIV分别为(50.2±0.7)ng/ml对(67.3±0.9)ng/ml和PIIIP分别为(6.2±0.6)ng/ml对(8.3±0.5)ng/ml,差异显著(P＜0.05)。结论 应用利拉鲁肽治疗NAFLD合并2 型糖尿病患者能有效降低血糖,改善血管内皮功能,纠正脂代谢紊乱,对预防糖尿病患者大血管并发症可能有益。     

2013年河南省新生儿苯丙酮尿症筛查及质量评估

目的分析2013年河南省新生儿苯丙酮尿症（PKU）筛查结果并对三种（Lab、丰华、PE）筛查试剂进行质量评估。方法采用荧光分析法检测滤纸血片中苯丙氨酸（phe）浓度。结果郑州大学第三附属医院于2013年共筛查新生儿1030748例,全年确诊HPA患儿151例（1／6826）,男77例,女74例;对2013年3月--12月不同厂家的室内质控数据和筛查数据进行了统计,Lab、丰华和PE的低值质控和高值质控的批内变异系数分别为11．79％和10．17％,11．10％和7．72％,12．85％和12．49％;其中Lab试剂筛查新生儿432197例确诊57例,丰华试剂281522例新生儿确诊36例,PE试剂151853例新生儿确诊16例,经χ^2检验统计,三种试剂统计的HPA确诊阳性数无明显差异。结论河南省PKU发病率居国内较高水平,Lab、丰华和PE三种试剂质量是稳定的,均可用于PKU筛查。     

大黄联合电针促进重症急性胰腺炎胃肠道功能复苏的临床研究

重症急性胰腺炎（SAP）起病凶险、进展迅速、并发症多、预后差、病死率高,常引起全身炎症反应,胃肠道在SAP起病早期首先受累,表现为胃潴留、十二指肠排空迟缓及肠麻痹等症状,如不及时处理,常会导致水电解质紊乱、酸碱失衡,菌群移位、呼吸循环受限、全身感染等严重后果。故胃肠道功能复苏在SAP的早期治疗中具有不可忽视的作用。本研究观察了大黄联合电针对该病的治疗效果,报告如下。     

去乙酰化酶1在消化道肿瘤中的研究进展

目的总结去乙酰化酶1(SIRT1)分子在消化道恶性肿瘤发生和发展过程中所起的重要作用。方法查阅近年来国内外关于消化道肿瘤发生发展过程中SIRT1分子作用的文献并作综述。结果 SIRT1分子通过与中长链非编码RNA(LncRNA)、微小RNA(microRNA)和自噬相关联,在食管癌、胃癌、结直肠癌、肝癌和胰腺癌中高表达,影响消化道肿瘤的发生和发展。结论 SIRT1分子的异常表达与消化道肿瘤的发生和发展密切相关。     

二氢青蒿素对胰腺癌生长的抑制作用

Objective To investigate the anti-tumor activity of dihydroartemisinin in pancreatic cancer in vitro and in vivo. Methods For cultured cells,cell growth was determined by the MTT assay and apoptosis was evaluated by flow cytometry analysis stained with Annexin V-FITG/PI. The protein expression in BxPC-3 cells was analyzed by Western blot assay. BxPC-3 cells were injected subcutaneously into nude mice to establish pancreatic xenograft tumors and the tumor volume was monitored after exposure to dihydroartemisinin. Ki-67 staining and TUNEL assay were used to assess tumor cell proliferation and apoptosis in tumor tissue. Results After treatment by dihydroartemisinin in vitro, the proliferative inhibition rates of pancreatic cancer cells BxPC-3 and AsPC-1 reached up to (76.2 ± 3.5) % and (79.5 ± 2.9) %, and the apoptosis rates were up to (55.5 ± 3.2)% and (40.0 ± 3.5)%, the differences were significantly (P ＜ 0.01) compared with control [(2.0 ± 1.3) % and (0.9 ± 0.4) %]. Dihydroartemisinin inhibited the growth of pancreatic xenograft tumors in nude mice. The proliferation index and apoptusis index were (49.1 ± 3.9)% and (50.2 ± 4.4)% respectively in dihydroarternisinin 50 mg/kg treatment group, compared to those of (72.1 ± 3.3) % and (9.4 ± 2.9) % in control, the differences were significantly (P ＜0.01). Western blot assay indicated that dihydroartemisinin up-regulates expression of proliferation-associated protein p21WAF1 and down-regulates expression of PCNA, increases expression of apoptosis-associated protein Bax and decreases expression of Bcl-2 and activates caspase-9 in BxPC-3 cells. Conclusions Dihydroartemisinin exerts anti-tumor activity in pancreatic cancer both in vitro and in vivo by proliferation inhibition and apoptusis induction. Dihydroartemisinin can be used as a potential anti-tumor drug in pancreatic cancer.     

胰腺损伤性胰瘘35例临床分析

目的:探讨胰腺损伤性胰痿的防治原则与措施.方法:回顾性分析131例胰腺外伤患者的临床资料,对术后35例并发胰瘘患者行"损伤控制性"手术(damage control surgery,DCS)并实施围手术期综合治疗方案.结果:35例胰瘘患者中3例经引流管造影显示形成内瘘自愈,9例术后形成胰腺假性囊肿行Roux-on-Y囊肿空肠内引流术,2例因MODS、腹腔感染死亡,其余患者均治愈.随访3个月～5年,出院患者无因胰瘘并发症等相关因素死亡者.结论:胰腺损伤性胰瘘的防治需全方位考虑实施DCS及围手术期综合治疗方案,既要有效控制原发损伤,又要积极预防并发症.